Creative Planning
TTNP

Creative Planning’s Titan Pharmaceuticals TTNP Stock Holding History

Creative Planning’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$27K – 4734
2016
Q2 		$27K Buy
+1
New +$21.3K ﹤0.01% 2581

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Creative Planning's TTNP Position: Q3 2016 in Review

Creative Planning sold out of Titan Pharmaceuticals (TTNP) in Q3 2016, closing a stake of 1 share — an estimated $27K sold.

Creative Planning first reported a position in TTNP in Q2 2016 and held it in 1 quarter. The position peaked at $27K in Q2 2016. 47 funds tracked by Wall St. Rank hold TTNP as of Q3 2016.

  • Creative Planning reported no remaining Titan Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Creative Planning sold 1 Titan Pharmaceuticals share in Q3 2016, an estimated $27K.
  • Creative Planning first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Creative Planning's Titan Pharmaceuticals position peaked at $27K in Q2 2016.
  • 47 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2016.

Based on Creative Planning's 13F filing for Q3 2016, filed 12 Oct 2016.